{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:14:54Z","timestamp":1773152094085,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ygyno.2025.10.016","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T19:00:58Z","timestamp":1761591658000},"page":"53-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The impact of romiplostim use for chemotherapy induced thrombocytopenia on immediate and long-term outcomes in gynecologic malignancies"],"prefix":"10.1016","volume":"203","author":[{"given":"Surabhi","family":"Tewari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellery","family":"Koelker-Wolfe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Pelletier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"St Laurent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"Matulonis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2025.10.016_bb0005","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7429","article-title":"Romiplostim in chemotherapy-induced thrombocytopenia: a review of the literature","volume":"13","author":"Soff","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.ygyno.2025.10.016_bb0010","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/bjh.20037","article-title":"Chemotherapy-induced thrombocytopenia: modern diagnosis and treatment","volume":"206","author":"Song","year":"2025","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ygyno.2025.10.016_bb0015","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.3324\/haematol.2020.251900","article-title":"A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies","volume":"106","author":"Al-Samkari","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.ygyno.2025.10.016_bb0020","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/17474086.2021.1924053","article-title":"Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia","volume":"14","author":"Al-Samkari","year":"2021","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.ygyno.2025.10.016_bb0025","first-page":"168","article-title":"Chemotherapy-induced thrombocytopenia and clinical bleeding in patients with gynecologic malignancy","volume":"36","author":"Hashiguchi","year":"2015","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.10.016_bb0030","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ygyno.2011.10.003","article-title":"Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer","volume":"124","author":"Nagel","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.10.016_bb0035","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ygyno.2018.07.021","article-title":"Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG oncology\/gynecologic oncology group study","volume":"151","author":"Olawaiye","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.10.016_bb0040","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ygyno.2012.12.017","article-title":"Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer","volume":"129","author":"Hanna","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.10.016_bb0045","article-title":"Colony-stimulating factors for chemotherapy-induced febrile neutropenia","volume":"2014","author":"Mhaskar","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ygyno.2025.10.016_bb0050","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1093\/annonc\/mdt226","article-title":"The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials","volume":"24","author":"Lyman","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2025.10.016_bb0055","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","article-title":"Impact of primary prophylaxis with granulocyte Colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review","volume":"25","author":"Kuderer","year":"2007","journal-title":"JCO"},{"key":"10.1016\/j.ygyno.2025.10.016_bb0060","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.tracli.2022.08.147","article-title":"Platelet transfusion in adults: an update","volume":"30","author":"Garraud","year":"2023","journal-title":"Transfus. Clin. Biol."},{"key":"10.1016\/j.ygyno.2025.10.016_bb0065","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3389\/fimmu.2015.00028","article-title":"Platelet transfusion - the new immunology of an old therapy","volume":"6","author":"Stolla","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ygyno.2025.10.016_bb0070","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1200\/JCO.2001.19.5.1519","article-title":"American Society of Clinical Oncology, platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology","volume":"19","author":"Schiffer","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.10.016_bb0075","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1182\/blood.2023022883","article-title":"How I treat patients who are refractory to platelet transfusions","volume":"145","author":"Nahirniak","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.ygyno.2025.10.016_bb0080","doi-asserted-by":"crossref","first-page":"364","DOI":"10.7326\/0003-4819-132-5-200003070-00005","article-title":"Recombinant human Thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer","volume":"132","author":"Vadhan-Raj","year":"2000","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ygyno.2025.10.016_bb0085","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/hematology.2022000374","article-title":"Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem","volume":"2022","author":"Al-Samkari","year":"2022","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.ygyno.2025.10.016_bb0090","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/bjh.12260","article-title":"Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy","volume":"161","author":"Kuter","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ygyno.2025.10.016_bb0095","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.2147\/DDDT.S299591","article-title":"A review of romiplostim mechanism of action and clinical applicability","volume":"15","author":"Bussel","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ygyno.2025.10.016_bb0100","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e24137","article-title":"Romiplostim for chemotherapy induced thrombocytopenia in solid tumors: a meta-analysis","volume":"42","author":"Sainatham","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.ygyno.2025.10.016_bb0105","article-title":"Use of romiplostim for antineoplastic therapy-induced thrombocytopenia in gynecologic and breast cancers","volume":"53","author":"Moufarrij","year":"2024","journal-title":"Gynecol. Oncol. Rep."},{"key":"10.1016\/j.ygyno.2025.10.016_bb0110","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J. Biomed. Inform."},{"key":"10.1016\/j.ygyno.2025.10.016_bb0115","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3324\/haematol.2021.279512","article-title":"Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies","volume":"107","author":"Kuter","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.ygyno.2025.10.016_bb0120","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1200\/JCO.1992.10.4.520","article-title":"Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer","volume":"10","author":"Jodrell","year":"1992","journal-title":"JCO"},{"key":"10.1016\/j.ygyno.2025.10.016_bb0125","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1200\/JCO.2001.19.4.1137","article-title":"Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia","volume":"19","author":"Elting","year":"2001","journal-title":"JCO"},{"key":"10.1016\/j.ygyno.2025.10.016_bb0130","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1200\/JCO.18.01931","article-title":"Romiplostim treatment of chemotherapy-induced thrombocytopenia","volume":"37","author":"Soff","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.ygyno.2025.10.016_bb0135","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12672-023-00616-3","article-title":"Chemotherapy-induced thrombocytopenia: literature review","volume":"14","author":"Gao","year":"2023","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.ygyno.2025.10.016_bb0140","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1182\/blood.V64.5.1036.1036","article-title":"Busulfan-induced chronic bone marrow failure: changes in cortical bone, marrow stromal cells, and adherent cell colonies","volume":"64","author":"McManus","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.ygyno.2025.10.016_bb0145","first-page":"179","article-title":"Genes and variants in hematopoiesis-related pathways are associated with gemcitabine\/carboplatin-induced thrombocytopenia","volume":"20","author":"Bj\u00f6rn","year":"2020","journal-title":"Pharm. J."},{"key":"10.1016\/j.ygyno.2025.10.016_bb0150","doi-asserted-by":"crossref","first-page":"6290","DOI":"10.3390\/ijms23116290","article-title":"Carboplatin-induced thrombocytopenia through JAK2 downregulation, S-Phase cell cycle arrest and apoptosis in megakaryocytes","volume":"23","author":"Wu","year":"2022","journal-title":"IJMS"},{"key":"10.1016\/j.ygyno.2025.10.016_bb0155","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000326801","article-title":"Thrombotic thrombocytopenic purpura and gemcitabine","volume":"4","author":"Kasi","year":"2011","journal-title":"Case Rep. Oncol."},{"key":"10.1016\/j.ygyno.2025.10.016_bb0160","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S1470-2045(07)70203-6","article-title":"Gemcitabine-associated thrombotic thrombocytopenic purpura","volume":"8","author":"Zupancic","year":"2007","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2025.10.016_bb0165","series-title":"Managing Adverse Effects Associated with Poly (ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Synthesis of Clinical Trial and Real-World Data","author":"Friedlander","year":"2023"},{"key":"10.1016\/j.ygyno.2025.10.016_bb0170","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/10781552231219003","article-title":"Role of thrombopoietin receptor agonists in chemotherapy-induced thrombocytopenia: a meta-analysis","volume":"31","author":"Gurumurthy","year":"2025","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.ygyno.2025.10.016_bb0175","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26040","article-title":"High dose romiplostim as a rescue therapy for adults with severe bleeding and refractory immune thrombocytopenia","volume":"96","author":"Roumier","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ygyno.2025.10.016_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.113624","article-title":"G-CSF administration results in thrombocytopenia by inhibiting the differentiation of hematopoietic progenitors into megakaryocytes","volume":"169","author":"Li","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ygyno.2025.10.016_bb0185","first-page":"544","article-title":"Impact of G-CSF administration post-allogeneic hematopoietic stem-cell transplantation on outcomes: a systematic review and meta-analysis","volume":"11","author":"Gupta","year":"2021","journal-title":"Am. J. Blood Res."},{"key":"10.1016\/j.ygyno.2025.10.016_bb0190","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.exphem.2005.01.009","article-title":"Granulocyte and granulocyte-macrophage colony-stimulating factors in allografts: uses, misuses, misconceptions, and future applications","volume":"33","author":"Ringd\u00e9n","year":"2005","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.ygyno.2025.10.016_bb0195","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/0140-6736(93)90394-V","article-title":"Granulocyte colony-stimulating factor and platelet aggregation","volume":"341","author":"Shimoda","year":"1993","journal-title":"Lancet"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825010406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825010406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T22:35:37Z","timestamp":1773095737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825825010406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":39,"alternative-id":["S0090825825010406"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.10.016","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of romiplostim use for chemotherapy induced thrombocytopenia on immediate and long-term outcomes in gynecologic malignancies","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}